St Jude Medical Stock To Go Ex-dividend Tomorrow (STJ)

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model.

NEW YORK ( TheStreet) -- The ex-dividend date for St Jude Medical (NYSE: STJ) is tomorrow, June 26, 2013. Owners of shares as of market close today will be eligible for a dividend of 25 cents per share. At a price of $45.13 as of 9:30 a.m. ET, the dividend yield is 2.2%.

The average volume for St Jude Medical has been 2.3 million shares per day over the past 30 days. St Jude Medical has a market cap of $12.66 billion and is part of the health care sector and health services industry. Shares are up 24.1% year to date as of the close of trading on Monday.

St. Jude Medical, Inc. develops, manufactures, and distributes cardiovascular and implantable neurostimulation medical devices worldwide. It operates in two divisions, Cardiovascular and Ablation Technologies, and Implantable Electronic Systems. The company has a P/E ratio of 17.8, equal to the S&P 500 P/E ratio of 17.7.

  • EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.

TheStreet Ratings rates St Jude Medical as a buy. The company's strengths can be seen in multiple areas, such as its solid stock price performance, increase in net income, notable return on equity, growth in earnings per share and expanding profit margins. We feel these strengths outweigh the fact that the company shows weak operating cash flow. You can view the full St Jude Medical Ratings Report.

See our dividend calendar or top-yielding stocks list.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more..
null

If you liked this article you might like

Can Abbott Outperform Despite Alere?

Abbott Shares Dip on Mixed Fourth-Quarter Earnings

Abbott Labs: Diagnosing Growth in 2017

Abbott Laboratories Can Merge With St. Jude Medical: FTC

FTC Allows Abbott to Spin Off Units, Buy St. Jude Medical